Equillium Inc Dossier
Qualitative Analysis
Business overview
Equillium, Inc. is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company's pipeline consists of several novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its lead clinical programs and platforms include EQ504, a novel, orally administered, colon-targeted small molecule aryl hydrocarbon receptor (AhR) modulator entering Phase 1 clinical development for ulcerative colitis, and EQ302, a preclinical-stage bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery to treat celiac disease. Equillium previously co-funded and developed itolizumab (EQ001) under a collaboration with Biocon and an asset purchase agreement with Ono Pharmaceutical, which expired in late 2024.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing EQ504, a novel oral small molecule AhR modulator, into clinical development for severe inflammatory diseases.
Expected impact: Establishes clinical proof-of-mechanism for a non-immunosuppressive therapeutic approach to severe inflammatory disorders.
Sharpening therapeutic focus on the AhR modulator platform (EQ504) and winding down historical clinical programs. This included terminating the collaboration and license agreement with Biocon Limited for itolizumab on September 30, 2025, and pausing activities related to EQ101 and EQ302.
Expected impact: Significantly reduced R&D and G&A expenses, extending the company's cash runway into 2029.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Ariagen, Inc. provided Equillium with the intellectual property and development rights to the novel aryl hydrocarbon receptor (AhR) platform, including the lead asset EQ504.
Financial impact: Assumed liabilities of $0.5 million at closing, with potential obligations of up to $55.0 million in future regulatory approval milestones.